中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2014年
38期
2988-2991
,共4页
盛锡楠%孔燕%汤欢%连斌%毛丽丽%迟志宏%崔传亮%斯璐%王轩
盛錫楠%孔燕%湯歡%連斌%毛麗麗%遲誌宏%崔傳亮%斯璐%王軒
성석남%공연%탕환%련빈%모려려%지지굉%최전량%사로%왕헌
肾肿瘤%多态性,单核甘酸%舒尼替尼%血小板减少
腎腫瘤%多態性,單覈甘痠%舒尼替尼%血小闆減少
신종류%다태성,단핵감산%서니체니%혈소판감소
Kidney neoplasms%Polymorphisms,single nucleotide%Sunitinib%Thrombocytopenia
目的 探讨在舒尼替尼药效学途径上血小板衍生生长因子受体基因多态性与舒尼替尼治疗后血小板减少之间的相关性.方法 对93例接受舒尼替尼标准剂量治疗的晚期肾透明细胞癌患者,治疗前外周血标本进行PDGFR(rs35597368,rs1800810)基因多态性检测,记录患者治疗后发生的血小板减少分级,评价基因多态性与血小板减少严重性之间的相关性.结果 SNP1580T/C型(rs35597368)检测成功率为95.7％ (89/93),基因型分布为:TT型71例(79.8％),TC型17例(19.1％),CC型1例(1.1％);SNP1171C/G型(rs1800810)检测成功率为96.8％(90/93),基因型分布为:CC型66例(73.3％),CG型24例(26.7％),rs35597368、rs1800810基因型分布符合Hardy-Weinberg遗传平衡定律.rs35597368位点TT、TC、CC基因型3/4级严重血小板减少发生率分别为29.6％、29.4％及100％,各基因型差异无统计学意义(P =0.313);rs1800810的CG基因型与CC基因型3/4级血小板减少发生率分别为45.8％和34.2％,两者差异有统计学意义(P =0.048).结论 晚期肾透明细胞癌人群应用舒尼替尼治疗后,rs1800810的CG基因型患者比CC基因型患者发生3/4级血小板减少的可能性更大,可为预测舒尼替尼导致血小板减少寻找合适的生物标志物提供帮助,从而有助于实现个体化靶向治疗.
目的 探討在舒尼替尼藥效學途徑上血小闆衍生生長因子受體基因多態性與舒尼替尼治療後血小闆減少之間的相關性.方法 對93例接受舒尼替尼標準劑量治療的晚期腎透明細胞癌患者,治療前外週血標本進行PDGFR(rs35597368,rs1800810)基因多態性檢測,記錄患者治療後髮生的血小闆減少分級,評價基因多態性與血小闆減少嚴重性之間的相關性.結果 SNP1580T/C型(rs35597368)檢測成功率為95.7％ (89/93),基因型分佈為:TT型71例(79.8％),TC型17例(19.1％),CC型1例(1.1％);SNP1171C/G型(rs1800810)檢測成功率為96.8％(90/93),基因型分佈為:CC型66例(73.3％),CG型24例(26.7％),rs35597368、rs1800810基因型分佈符閤Hardy-Weinberg遺傳平衡定律.rs35597368位點TT、TC、CC基因型3/4級嚴重血小闆減少髮生率分彆為29.6％、29.4％及100％,各基因型差異無統計學意義(P =0.313);rs1800810的CG基因型與CC基因型3/4級血小闆減少髮生率分彆為45.8％和34.2％,兩者差異有統計學意義(P =0.048).結論 晚期腎透明細胞癌人群應用舒尼替尼治療後,rs1800810的CG基因型患者比CC基因型患者髮生3/4級血小闆減少的可能性更大,可為預測舒尼替尼導緻血小闆減少尋找閤適的生物標誌物提供幫助,從而有助于實現箇體化靶嚮治療.
목적 탐토재서니체니약효학도경상혈소판연생생장인자수체기인다태성여서니체니치료후혈소판감소지간적상관성.방법 대93례접수서니체니표준제량치료적만기신투명세포암환자,치료전외주혈표본진행PDGFR(rs35597368,rs1800810)기인다태성검측,기록환자치료후발생적혈소판감소분급,평개기인다태성여혈소판감소엄중성지간적상관성.결과 SNP1580T/C형(rs35597368)검측성공솔위95.7％ (89/93),기인형분포위:TT형71례(79.8％),TC형17례(19.1％),CC형1례(1.1％);SNP1171C/G형(rs1800810)검측성공솔위96.8％(90/93),기인형분포위:CC형66례(73.3％),CG형24례(26.7％),rs35597368、rs1800810기인형분포부합Hardy-Weinberg유전평형정률.rs35597368위점TT、TC、CC기인형3/4급엄중혈소판감소발생솔분별위29.6％、29.4％급100％,각기인형차이무통계학의의(P =0.313);rs1800810적CG기인형여CC기인형3/4급혈소판감소발생솔분별위45.8％화34.2％,량자차이유통계학의의(P =0.048).결론 만기신투명세포암인군응용서니체니치료후,rs1800810적CG기인형환자비CC기인형환자발생3/4급혈소판감소적가능성경대,가위예측서니체니도치혈소판감소심조합괄적생물표지물제공방조,종이유조우실현개체화파향치료.
Objective To explore the genetic polymorphisms of PDGFR associated with thrombocytopenia in Chinese patients with metastatic clear-cell renal cell carcinoma (mcc-RCC) treated with sunitinib.Methods A total of 93 mcc-RCC patients treated with sunitinib were enrolled.Genotype analyses were performed before treatment and thrombocytopenia was recorded on the first three cycles of treatment.Genetic polymorphisms of PDGFR (rs35597368,rs1800810) were analyzed for a possible association with thrombocytopenia.Results The genotypes of rs35597368 and rs1800810 conformed to the Hardy-Weinberg law.No significant difference existed in grade 3/4 thrombocytopenia between rs35597368 TC and TT genotypes (29.6％ vs 29.4％,P =0.313).The rs1800810 CG genotype was associated with a higher risk for grade 3/4 thrombocytopenia as compared with CC genotype (45.8％ vs 34.2％,P =0.048).Conclusions The risk for grade 3/4 thrombocytopenia increases in the presence of allele genotype in PDGFR 1171C/G.And a biomarker may be customized for patients with mcc-RCC treated with sunitinib.
